




RealRate

PHARMACEUTICAL 2026

Cumberland Pharmaceuticals INC
Rank 101 of 178



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cumberland Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cumberland Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Cumberland Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 213%, being 17% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	37,060
Cost of Goods Sold	6,667
Intangible Assets	14,942
Liabilities, Current	36,745
Liabilities, Non-Current	10,294
Other Assets	24,557
Other Compr. Net Income	0
Other Expenses	23,669
Other Liabilities	5,241
Other Net Income	464
Other Revenues	44,521
Property and Equipment	265
Research and Development	5,566
Selling, General and Administrative Expense	11,947

Output Variable	Value in 1000 USD
Assets	76,824
Liabilities	52,280
Expenses	47,850
Revenues	44,521
Stockholders Equity	24,544
Net Income	-2,865
Comprehensive Net Income	-2,865
BaseVar	110,969
ECR before Limited Liability	78%
Economic Capital Ratio	213%